SHANGHAI, China and SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced ...

Zai Lab (ZLAB) Limited announced that it has commenced an underwritten public offering of $200M of American depositary shares, ADSs, each representing ten ordinary shares of the company with a par ...

Also featured at AACR 2024 will be Zai Lab’s Phase 1 study (NCT05859464) of ZL-1218, an anti-CCR8 antibody that blocks regulatory T cells (Treg) which suppress antitumor immunity in tumor tissue ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a preclinical study of ZL-1503, the company’s internally discover ...

SHANGHAI & CAMBRIDGE, Mass., August 07, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2025, along with recent product highlights and ...